Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 205,853,910 papers from all fields of science
Search
Sign In
Create Free Account
SU 11654
Known as:
SU-11654
, SU11654
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Broader (1)
toceranib phosphate
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Review
2013
Review
2013
A model of study for human cancer: Spontaneous occurring tumors in dogs. Biological features and translation for new anticancer therapies.
G. Ranieri
,
C. Gadaleta
,
+5 authors
D. Ribatti
Critical reviews in oncology/hematology
2013
Corpus ID: 9043729
Review
2011
Review
2011
Abstract SY28-01: Spontaneous cancer in dogs: Opportunities for preclinical evaluation of novel therapies
C. London
2011
Corpus ID: 75785348
Spontaneous cancers are common in the pet dog population with estimated 60% of dogs that live to 10 years of age developing…
Expand
2010
2010
Pharmacokinetic properties of toceranib phosphate (Palladia, SU11654), a novel tyrosine kinase inhibitor, in laboratory dogs and dogs with mast cell tumors.
M. Yancey
,
D. Merritt
,
S. Lesman
,
J. Boucher
,
G. Michels
Journal of veterinary pharmacology and…
2010
Corpus ID: 19406269
Toceranib phosphate (Palladia, SU11654), an oral tyrosine-kinase inhibitor, is under investigation for the treatment of mast cell…
Expand
Review
2010
Review
2010
Distribution, metabolism, and excretion of toceranib phosphate (Palladia, SU11654), a novel tyrosine kinase inhibitor, in dogs.
M. Yancey
,
D. Merritt
,
J. A. White
,
S. Marsh
,
C. Locuson
Journal of veterinary pharmacology and…
2010
Corpus ID: 22648114
Toceranib phosphate (Palladia, SU11654), a multireceptor tyrosine kinase inhibitor with anti-tumor and anti-angiogenic activity…
Expand
Highly Cited
2009
Highly Cited
2009
Multi-center, Placebo-controlled, Double-blind, Randomized Study of Oral Toceranib Phosphate (SU11654), a Receptor Tyrosine Kinase Inhibitor, for the Treatment of Dogs with Recurrent (Either Local or…
C. London
,
P. Malpas
,
+11 authors
G. Michels
Clinical Cancer Research
2009
Corpus ID: 17970290
Purpose: The purpose of this study was to determine the objective response rate (ORR) following treatment of canine mast cell…
Expand
Highly Cited
2008
Highly Cited
2008
The novel HSP90 inhibitor STA-9090 exhibits activity against Kit-dependent and -independent malignant mast cell tumors.
Tzu-yin Lin
,
M. Bear
,
+4 authors
C. London
Experimental hematology
2008
Corpus ID: 1821839
2006
2006
Evaluation of dysregulation of the receptor tyrosine kinases Kit, Flt3, and Met in histiocytic sarcomas of dogs.
R. Zavodovskaya
,
A. Liao
,
+4 authors
C. London
American journal of veterinary research
2006
Corpus ID: 24936070
OBJECTIVE To evaluate canine histiocytic sarcoma cell lines and tumor samples for dysregulation of the Kit/stem-cell factor (SCF…
Expand
Highly Cited
2003
Highly Cited
2003
Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies.
C. London
,
A. Hannah
,
+10 authors
J. Cherrington
Clinical cancer research : an official journal of…
2003
Corpus ID: 3028255
PURPOSE The purpose of the following study was to investigate the safety and efficacy of the novel multitargeted indolinone…
Expand
Highly Cited
2003
Highly Cited
2003
Proof of target for SU11654: inhibition of KIT phosphorylation in canine mast cell tumors.
N. Pryer
,
Leslie B. Lee
,
+4 authors
C. London
Clinical cancer research : an official journal of…
2003
Corpus ID: 12107797
PURPOSE The purpose of this study was to evaluate the effect of the receptor tyrosine kinase inhibitor SU11654 on the activity of…
Expand
Highly Cited
2002
Highly Cited
2002
Inhibition of constitutively active forms of mutant kit by multitargeted indolinone tyrosine kinase inhibitors.
A. Liao
,
May Chien
,
+4 authors
C. London
Blood
2002
Corpus ID: 12123261
Mutations in the proto-oncogene c-kit, including point mutations, deletions, or duplications in the negative regulatory…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
,
Terms of Service
, and
Dataset License
ACCEPT & CONTINUE